Long-COVID — the constellation of persistent symptoms that follow acute COVID-19 infection — affects an estimated 10-30% of those who contract the virus. Symptoms range from brain fog and fatigue to shortness of breath, heart palpitations, and joint pain. Many patients have been debilitated for two or more years with little relief from conventional medicine.
Into this treatment vacuum, a growing number of clinicians and patients have reported that ivermectin — particularly when combined with other anti-inflammatory agents — produces meaningful improvement in long-COVID symptoms.
The Persistence Hypothesis
The leading theory for long-COVID involves viral persistence — the idea that fragments of SARS-CoV-2 RNA (or possibly intact virus in tissue reservoirs) continue to trigger immune activation long after the acute infection. The FLCCC has incorporated this hypothesis into their long-COVID treatment protocol, called I-RECOVER.
Ivermectin's role in this protocol is based on its documented ability to interfere with viral importin receptors, potentially limiting ongoing viral replication or viral fragment-driven inflammation. Several observational studies and case series have documented improvement in long-COVID patients treated with extended ivermectin protocols.
Patient Reports
Online communities of long-COVID patients number in the hundreds of thousands. Within these communities, ivermectin has been one of the most widely discussed experimental treatments. Patient-reported outcomes consistently describe improvement in cognitive function (brain fog), energy levels, and respiratory symptoms after ivermectin courses ranging from two to eight weeks.
These are not scientific proof. But they represent a signal — and in the absence of any effective conventional treatment for long-COVID, they are a signal that deserves rigorous clinical investigation rather than suppression.
The Medical Freedom Dimension
Long-COVID patients are desperate. Many have been told by their doctors that there is nothing to offer. The gatekeeping of potentially helpful medications like ivermectin in this context is particularly cruel — these are patients who have already suffered enormously and are being denied the opportunity to try a safe, inexpensive medication with a plausible mechanism of action.
The principle of patient autonomy — the bedrock of medical ethics — demands that patients with no good options have the right to access promising treatments with their physician's guidance.
The Path Forward
The FLCCC's I-RECOVER protocol is the most systematic publicly available framework for long-COVID treatment. It incorporates ivermectin, low-dose naltrexone, fluvoxamine, and other agents based on mechanistic rationale and clinical experience. It is available free of charge at the FLCCC website.
Key Takeaway: Long-COVID patients deserve access to every potentially helpful tool — including ivermectin — and the growing body of patient reports and clinical observations strongly supports urgent, unbiased clinical investigation of its role in long-COVID recovery.